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Gender Differences in Sensitivity to
Adrenergic Agonists of Forearm Resistance Vasculature
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OBJECTIVES The goal of this study was to investigate the mechanism of reduced vasoconstrictor sensitivity
to norepinephrine in women compared with men.
BACKGROUND b2-adrenergic agonists such as albuterol dilate forearm resistance vessels, partly by activating
the L-arginine/nitric oxide pathway. Norepinephrine (which acts as b- as well as
a-adrenergic receptors) causes less forearm vasoconstriction in women than it does in men.
This could be explained by a greater sensitivity to b2-receptor stimulation in women than in
men.
METHODS Forearm blood flow was measured by venous occlusion plethysmography in healthy women
(days 10 to 14 of the menstrual cycle) and in men. Drugs were administered via the brachial
artery in three separate protocols: albuterol 6 NG-monomethyl-L-arginine (an inhibitor of
nitric oxide synthase); substance P, nitroprusside and verapamil (control vasodilators);
norepinephrine (6 propranolol, a b-adrenergic receptor antagonist).
RESULTS Vasodilator responses to albuterol were greater in women than they were in men (p 5 0.02
by analysis of variance). NG-monomethyl-L-arginine reduced these similarly in men and
women. Responses to control vasodilators were less in women than they were in men (each
p , 0.05). Norepinephrine caused less vasoconstriction in women than it did in men (p 5
0.02). Propranolol did not influence basal flow in either gender nor responses of men to
norepinephrine but increased vasoconstriction to each dose of norepinephrine in women (p ,
0.0001 for interaction between gender and propranolol). Responses to norepinephrine
coinfused with propranolol were similar in men and women.
CONCLUSIONS Stimulation of b2-adrenergic receptors causes greater forearm vasodilation in premenopausal
women, at midmenstrual cycle, than it does in men. This is sufficient to explain why
vasoconstriction to brachial artery norepinephrine is attenuated in such women. (J Am Coll
Cardiol 2000;36:1233–8) © 2000 by the American College of Cardiology
Resistance vessel tone is an important determinant of
arterial blood pressure and regional blood flow. It is con-
trolled by mediators from adrenergic nerves and vascular
endothelium. Norepinephrine is the principal peripheral
sympathetic neurotransmitter, and it constricts blood vessels
through actions on a-adrenergic receptors. It is also a
powerful agonist at b1-adrenergic receptors but is much less
potent at b2-receptors (1). b2- (but not b1) agonists
administered into the brachial artery dilate forearm resis-
tance vessels, and this action is mediated, in part, through
activation of the L-arginine/nitric oxide (NO) pathway (2).
Forearm b-adrenergic receptor-mediated vasodilation is
impaired, without alteration of norepinephrine spillover, in
borderline hypertension (3), suggesting that altered b2-
adrenergic function may have important pathophysiological
consequences. We have observed a marked difference be-
tween men and women in sensitivity to the vasoconstrictor
action of norepinephrine on forearm resistance vessels (4).
Women were studied during the follicular phase of the
menstrual cycle when endogenous estrogen concentrations
are high and unopposed by progesterone. Such women are
relatively insensitive to the vasoconstrictor action of norepi-
nephrine infused into the brachial artery. Reduced sensitiv-
ity to the vasoconstrictor action of norepinephrine could
contribute to gender-related differences in the incidence and
outcome of vascular disease (5–7), which are profound and
incompletely explained by associations with known cardio-
vascular risk factors (8–10).
The mechanism of reduced sensitivity in women to the
vasoconstrictor action of norepinephrine in forearm resis-
tance vessels is not known. Evidence from animal studies
has been conflicting (11–15). Estrogen replacement therapy
reduces vasoconstrictor responses to norepinephrine in peri-
menopausal women (16), possibly due to increased NO
synthesis (17). We hypothesized that reduced sensitivity to
the vasoconstrictor action of norepinephrine in women
could be a consequence of increased sensitivity to b2-
adrenergic receptor stimulation, offsetting the vasoconstric-
tor effect of a-adrenergic receptor activation. To test this
possibility, we compared the sensitivity of forearm resistance
vasculature to the vasodilator action of albuterol (a b2-
adrenergic receptor agonist) in men and women. We also
studied substance P, nitroprusside and verapamil, vasodila-
tors that are not b2-adrenergic agonists and act by diverse
mechanisms (18–20) to exclude the possibility that gender-
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related structural or other differences in this vascular bed
could account in a nonspecific way for differences in
response to vasodilators. To determine whether b-receptor
stimulation was quantitatively sufficient to account for the
reduced effect of norepinephrine in women, we studied the
effect of coinfusing propranolol (a b-adrenergic receptor
antagonist) with norepinephrine.
METHODS
Subjects. Subjects were recruited by advertisement in
southeast London. All were white, nonsmoking and receiv-
ing no medication (including contraceptive or other hor-
monal preparations). Other characteristics are summarized
in Table 1.
Materials and experimental protocols. Drugs were ob-
tained from: Allen and Hanburys, Uxbridge, United King-
dom: albuterol sulfate; Clinalfa, Laufelfingen, Switzerland:
NG-monomethyl-L-arginine hydrochloride (L-NMMA),
substance P; Roche Products, Basel, Switzerland: sodium
nitroprusside; Baker Norton, Harlow, United Kingdom:
verapamil hydrochloride; Sanofi Winthrop, Guildford,
United Kingdom: norepinephrine acid tartrate and Zeneca,
Wilmslow, United Kingdom: propranolol hydrochloride.
Protocols were approved by the St. Thomas’ Hospital
Research Ethics Committee. All subjects provided written
informed consent for their participation in the study. All the
women had regular menstrual cycles and were studied on
day 10 to 14. Studies were performed in the morning after
a light breakfast, in a quiet temperature controlled vascular
laboratory (24 to 26°C). A 27-gauge unmounted steel
needle (Cooper’s Needle Works, Birmingham, United
Kingdom) sealed with dental wax to an epidural cannula was
inserted into the left brachial artery using less than 1 ml of
1% lidocaine hydrochloride to provide local anesthesia. In
each protocol subjects rested supine for at least 30 min, and
saline (0.9% sodium chloride) was infused by a constant rate
pump for at least 12 min before baseline readings were
obtained. Throughout each experiment, saline (with or
without drug) was infused at a constant rate of 1 ml per
minute. Increasing doses of drugs were administered by
stepwise increments. Forearm blood flow was measured in
both arms using venous occlusion plethysmography (21)
with electrically calibrated strain gauges (22). Blood flow to
the hands was occluded by wrist cuffs during measurements.
The pressure in the upper arm cuffs was 40 mm Hg. Drug
effects (at the doses used) reached a plateau within 2 min.
Measurements were made from 2 to 4 min. Flows were
recorded for approximately 10 s in every 15 s, and the mean
of the final five measurements was used for analysis. Three
separate protocols were employed:
Sensitivity to albuterol and effect of L-NMMA. Albuterol
(0.35, 1, 3.5 and 10 nmol min21) was infused with a saline
vehicle. Saline was then infused alone for 24 min during
which blood flow returned to baseline. A second series of
baseline measurements was recorded before infusion of
L-NMMA (16 mmol min21). Albuterol (0.35, 1, 3.5 and 10
nmol min21) was then coinfused with L-NMMA.
Sensitivity to substance P, nitroprusside and verapamil. In
separate experiments substance P (0.3, 1, 3 and 10 pmol
min21), nitroprusside (3, 6, 12 and 24 nmol min21) and
verapamil (20, 40, 80 and 160 nmol min21) were infused
sequentially with intervening saline periods ($24 min)
during which blood flow returned to baseline.
Sensitivity to norepinephrine and effect of propranolol. Nor-
epinephrine (60, 120 and 240 pmol min21) was infused
with saline. Saline was then infused alone for at least 18 min
during which blood flow returned to baseline. A second
series of baseline measurements was recorded before infu-
sion of propranolol (190 nmol min21). Norepinephrine (60,
120 and 240 pmol min21) was then coinfused with pro-
pranolol (190 nmol min21).
Statistical analysis. Unless otherwise stated values are
expressed as means 6 SEM. Vasodilator responses were
expressed as increase in blood flow in the infused arm above
the immediately preceding baseline period. Vasoconstrictor
responses were expressed as percentage reduction in forearm
blood flow (infused: control arm) relative to the immediately
preceding baseline. Vasodilator and vasoconstrictor re-
sponses are most reproducibly expressed in these forms (23).
Area under the dose-response curve (expressed in arbitrary
units) was used as a summary measure (24). Repeated
measures analysis of variance was used to assess differences
in blood flow responses across the doses used between men
and women and to assess effects of antagonists (L-NMMA
or propranolol) on blood flow responses separately within
each gender. In addition to these main effects, we sought
interactions between gender and antagonist on drug responses.
All p values refer to main effects except where it is stated that
they refer to tests for an interaction. Differences were consid-
ered significant at a value of p , 0.05 (two-sided).
Abbreviations and Acronyms
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
Table 1. Characteristics of Subjects*
Characteristics Women Men
Age (yr) 27.6 6 5.3 28.3 6 7.1
Weight (kg) 66.1 6 10.6 76.0 6 11.2†
Height (m) 1.67 6 0.05 1.80 6 0.09
Plasma glucose (mmol/L) 4.3 6 0.4 4.3 6 0.7
Serum cholesterol (mmol/L) 4.58 6 1.0 4.35 6 0.7
Systolic blood pressure (mm Hg) 115 6 13 123 6 9
Diastolic blood pressure (mm Hg) 66 6 9 69 6 7
Mean arterial pressure (mm Hg) 84 6 10 88 6 6
Forearm circumference (mm) 237 6 13 260 6 16‡
Forearm length (mm) 244 6 11 266 6 12‡
Baseline blood flow
(ml min21 100 ml21)
1.96 6 0.60 2.63 6 1.04†
*Plus-minus values are mean 6 SD. The three protocols were performed on 8/8,
10/10 and 8/8 (men/women) of these subjects (21 men, 17 women). †p , 0.05
compared with values in women; ‡p , 0.001 compared with values in women.
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RESULTS
Forearm blood flow in the noninfused arm did not change
significantly during drug infusion in men or women in any
protocol.
Sensitivity to albuterol and effect of L-NMMA. Albu-
terol caused a dose-dependent increase in forearm blood
flow in both genders, and vasodilator responses were greater
in women than they were in men (n 5 16; Fig. 1 and Table
2). NG-monomethyl-L-arginine caused similar reductions
in forearm blood flow, compared with the immediately
preceding baseline in men and women: 45 6 5% in men and
43 6 6% in women (p 5 0.83). Figure 1 shows the effect of
L-NMMA on responses to albuterol. NG-monomethyl-L-
arginine inhibited these in women (p 5 0.003) and in men
(p 5 0.002). NG-monomethyl-L-arginine reduced albuterol
area under the curve by 41 6 5% in women and by 45 6 9%
in men. Gender did not significantly influence inhibition of
albuterol by L-NMMA (p 5 0.66 for the interaction
between gender and inhibition), and responses to albuterol
during coinfusion with L-NMMA were greater in women
than they were in men (p 5 0.02).
Sensitivity to substance P, nitroprusside and verapamil.
Substance P, nitroprusside and verapamil each produced a
dose-dependent increase in blood flow in both genders.
Responses to each of these vasodilators were less in women
than they were in men (each p , 0.05, Table 2).
Sensitivity to norepinephrine and effect of propranolol.
Each dose of norepinephrine (60, 120 and 240 pmol min21)
reduced forearm blood flow ratio in men. In women there
was a tendency toward an increase in blood flow at the
lowest dose and reduced blood flow at higher doses (Fig. 2).
The difference in responses between men and women was
significant (p 5 0.02).
Propranolol had no significant effect on baseline blood
flow in either gender (p 5 0.49 in men, p 5 0.66 in women,
n 5 8 of each gender). Its effects on norepinephrine
responses are shown in Figure 2. Propranolol had no
significant effect (p 5 0.72) on responses to norepinephrine
in men but converted the mild increase in forearm blood
flow ratio observed at the lowest dose of norepinephrine in
women into a vasoconstrictor response and increased the
Figure 1. Forearm blood flow responses to albuterol (6 L-NMMA) in women and men. Bars indicate mean 6 SEM increase in blood flow above the
immediately preceding baseline. Open bars show responses to albuterol coinfused with saline; closed bars show responses to albuterol coinfused with
L-NMMA (16 mmol/min). Responses to albuterol were greater in women than they were in men (n 5 8 for each gender, p 5 0.02).
NG-monomethyl-L-arginine inhibited responses to albuterol (p , 0.003). Inhibition by L-NMMA was similar (p 5 0.83) in women and men.
L-NMMA 5 NG-monomethyl-L-arginine.
Table 2. Forearm Blood Flow Responses of Women and Men












Albuterol 0.35 2.3 6 0.5 1.2 6 0.3
1.0 4.5 6 0.7 3.0 6 0.3
3.5 6.9 6 0.9 4.7 6 0.4
10 10.4 6 1.1 6.8 6 0.5
AUC‡ 20.3 6 2.2 13.5 6 0.9 0.02
Substance P 0.0003 1.1 6 0.2 1.8 6 0.4
0.001 2.0 6 0.3 3.8 6 0.5
0.003 3.5 6 0.6 6.5 6 1.2
0.01 6.6 6 0.9 9.8 6 1.2
AUC‡ 9.4 6 1.3 16.2 6 2.3 0.02
Nitroprusside 3 2.6 6 0.4 4.1 6 0.4
6 3.5 6 0.5 5.8 6 0.7
12 4.2 6 0.5 6.9 6 0.7
24 5.4 6 0.8 8.5 6 0.7
AUC‡ 4.8 6 0.7 8.4 6 1.5 0.03
Verapamil 20 3.1 6 0.3 4.7 6 0.5
40 3.5 6 0.4 6.1 6 0.6
80 4.8 6 0.7 7.9 6 0.8
160 6.7 6 1.0 10.0 6 1.0
AUC‡ 6.3 6 1.0 10.5 6 1.3 0.04
*Increase in forearm blood flow above immediately preceding baseline; †for difference
of AUC between women and men; ‡area under the dose response curve (arbitrary
units) 6 SEM.
AUC 5 area under the dose response curve.
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vasoconstriction caused by the two higher doses (p 5 0.0001
for the interaction of gender with effect of propranolol on
norepinephrine response). During infusion of propranolol
with norepinephrine, vasoconstriction to norepinephrine in
women increased to the extent that responses in women
became similar to those in men (p 5 0.34).
DISCUSSION
Gender differences in basal and agonist-stimulated fore-
arm blood flow. Women are more sensitive than men to
the hypokalemic effect of inhaled b2-adrenergic receptor
agonist (terbutaline) (25), but gender differences in the
response of human resistance vasculature to b2-agonists
have not been described previously. The first main finding
of this study was that albuterol, a selective b2-adrenergic
receptor agonist, is a more potent forearm vasodilator in
women than it is in men. Forearm blood flow is predomi-
nantly to striated muscle, which accounts for a substantial
fraction of total peripheral vascular resistance. Other spe-
cialized vascular beds differ. Blood flow in the skin of the
hands is involved in thermoregulation, and finger blood flow
responses to another b-adrenergic agonist, isoproterenol,
are greater in men than they are in women (26). Vasocon-
striction to norepinephrine is potentiated by propranolol in
this vascular bed, where b-adrenergic agonists act on arte-
riovenous shunts (27). These contrasts highlight divergent
b-adrenergic effects in vascular beds serving different spe-
cialized functions and agree with previously reported diver-
gence between b-adrenergic sensitivity in different kinds of
blood vessels in humans in vivo (28).
Gender differences in responsiveness to brachial artery
administration of drugs that are unstable in blood (such as
acetylcholine) have been reported but are difficult to inter-
pret because they are strongly influenced by basal blood flow
and forearm length (29,30), which differ between unselected
groups of women and men. However, albuterol is relatively
stable in vivo, with an elimination half-life from the
circulation after systemic administration in the range of 3 to
5 h (31). Furthermore, we found that women are less
sensitive than men to three nonadrenergic vasodilators.
These findings were unexpected and have not been reported
previously. Since each of these vasodilators acts by a differ-
ent mechanism, the explanation possibly rests with a struc-
tural difference in forearm resistance vessels between women
and men. Differences between forearm length, circumfer-
ence and basal blood flow in women and men studied (Table
1) would be consistent with this. Baseline blood flow was
approximately 25% less in women than it was in men, and
a similar trend was observed previously (4). The explanation
for this is not known but, since blood flow is expressed per
100 ml of forearm volume, it is possible that it relates to
differences in forearm composition between the genders. A
greater proportion of fat to striated muscle in women could
account for the difference since fat is relatively poorly
perfused compared with muscle under basal conditions in a
warm environment. Despite the gender difference in re-
sponse to b2-adrenergic stimulation that we observed, it is
not likely that differences between genders in basal blood
flow are caused by differences in circulating catecholamines,
which are similar in men and women (32). Vasodilator
responses to drugs usually vary in parallel with basal flow,
possibly as a result of flow-dependent drug elimination in
arteries proximal to resistance vessels (30,33), and this may
explain the reduced vasodilator response to control agonists
in the women in this study. Whatever the explanation of
this reduced sensitivity, it makes the increased sensitivity to
albuterol in women more striking. Since the gender differ-
ence in sensitivity to albuterol is specific, it is possible that
Figure 2. Forearm blood flow responses to norepinephrine (6propranolol) in women and men. Bars indicate mean 6 SEM percent change in blood flow
ratio (infused/noninfused arm). Open bars show responses to norepinephrine coinfused with saline; closed bars show responses to norepinephrine coinfused
with propranolol (190 nmol/min). Reduction in forearm blood flow during norepinephrine infusion was significantly greater in men than it was in women
(n 5 8 for each gender, p 5 0.02). Propranolol coinfusion significantly increased the response to norepinephrine in women (p 5 0.0004) but not in men
(p 5 0.58). During infusion of propranolol, responses to norepinephrine were similar (p 5 0.34) in women and men.
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the increased sensitivity of women to albuterol is caused by
differences at, or downstream, from b2-adrenergic receptors
in forearm resistance vessels. This contrasts with the non-
specific reduction in sensitivity to isoproterenol in healthy
black American men in whom attenuated vasodilator re-
sponses are a generalized phenomenon (34).
Vasorelaxation mediated by b2-adrenergic receptors de-
pends on the presence of intact endothelium in some (35–40),
but not all (41–43), blood vessels. Human umbilical vein
endothelial cells express b2-adrenergic receptors, and b2-
adrenergic agonists stimulate adenylyl cyclase in these cells,
activating NO synthase (40). Vasodilation to isoproterenol
(2,44) and albuterol in forearm resistance vessels is inhibited by
L-NMMA in healthy men, whereas vasodilation to verapamil,
nitroprusside and prostacyclin are not (2). Vasodilation to
isoproterenol and albuterol is only partly inhibited by
L-NMMA, suggesting that b2-adrenergic vasodilation in the
forearm is only partly NO-mediated. These findings suggest
that b2-adrenergic vasodilation depends on activation of the
L-arginine/NO pathway in addition to the direct effects of
b2-adrenergic agonists on vascular smooth muscle (41–43).
The effect of L-NMMA on albuterol responses in women has
not been reported previously. This study confirms that
L-NMMA reduces basal forearm blood flow similarly in men
and women (4). The findings also demonstrate that
L-NMMA antagonizes forearm vasodilator responses to albu-
terol in women by a similar percentage as in men (41 6 5% in
women and 45 6 9% in men). Responses to albuterol during
inhibition of NO synthase remain greater in women than they
do in men. This suggests that NO-dependent and NO-
independent components of the b2-adrenergic response con-
tribute similarly to the albuterol response in women and men.
The simplest explanation for the increased sensitivity to albu-
terol in women is, thus, an increase in numbers of b2-
adrenergic receptors or increased activity of adenylyl cyclase
linked to these receptors. It is not possible to address this
directly in human forearm resistance vessels, but it is notewor-
thy that b2-adrenergic receptor density and receptor-coupled
adenylyl cyclase activity are increased in lymphocytes of women
compared with men and varies with the phase of the menstrual
cycle (45,46). If similar changes occur in endothelial and
vascular smooth muscle cells in forearm resistance vasculature
independent of an effect on a-adrenergic receptors, this could
account for the increased sensitivity to b2-adrenergic agonists
that we observed in women.
Effect of propranolol on forearm responses to norepi-
nephrine in men and women. We originally sought to
determine whether there is increased sensitivity in women
to b2-adrenergic receptor stimulation in forearm resistance
vessels to explore the hypothesis that this could explain the
blunted vasoconstriction to norepinephrine observed in
women during the follicular phase of the menstrual cycle
(4). The observations discussed above indicate that women
are, indeed, more sensitive to brachial artery infusion of
albuterol than men. This raises the question of whether this
difference is sufficient to account for the observed blunting
of vasoconstriction to norepinephrine in women. We ad-
dressed this by coinfusion of propranolol with norepinephrine,
arguing that, if the difference in sensitivity to norepinephrine
between men and women was caused by differences in
b-adrenergic receptor activation, this difference should be
abolished by blockade of b-adrenergic receptors.
Brachial artery administration of this dose of propranolol
in healthy men has been reported to have no effect on basal
forearm blood flow (47). The present findings confirm this
and extend it to healthy women. In addition, we observed
that propranolol has no significant effect on vasoconstrictor
responses to norepinephrine in men, indicating that there is
little or no b2-adrenergic receptor activation by these doses
of norepinephrine in men. In contrast, propranolol mark-
edly potentiates forearm vasoconstriction to norepinephrine
in women, and the second main finding of this study was
that propranolol completely abolished the gender difference
in sensitivity to norepinephrine. Thus, increased sensitivity
to b2-adrenergic receptor stimulation is quantitatively suf-
ficient to account for the observed attenuation of
norepinephrine-mediated vasoconstriction in women. Con-
sequently, it is not necessary to invoke differences in
a-adrenergic responsiveness to explain the observed gender
difference in responsiveness to norepinephrine in forearm
vasculature, in contrast with the cutaneous circulation where
there is a gender difference in adrenergic response (27) that
appears to be due to tonically increased sympathetic tone
with consequent down-regulation of a-adrenergic receptors.
Increased sensitivity of resistance vessels in striated mus-
cle to b2-adrenergic stimuli could represent an important
control mechanism in premenopausal women, and respon-
siveness to adrenergic receptor stimulation may contribute
to the pathogenesis of vascular disease. Forearm blood flow
responses to isoproterenol are attenuated in black men, and
it has been suggested that blunted vasodilator responses
mediated by b2-adrenergic receptors may play a part in the
pathogenesis of hypertension in this ethnic group (48). In
this study all subjects were white, and the findings suggest
the possibility that increased responses to b-adrenergic
stimuli could influence vascular function and contribute to
gender-related differences in the incidence or progression of
vascular disease in premenopausal women.
We concluded that a previously unrecognized gender
difference in forearm resistance vessel sensitivity to b2-
adrenergic receptor stimulation underlies reduced respon-
siveness of this vascular bed to norepinephrine in premeno-
pausal women.
Reprint requests and correspondence: Dr. J. M. Ritter, Depart-
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